IRADIMED CORP (NASDAQ:IRMD): Institutional Investors Aren’t Crazy About It

IRadimed Corporation (NASDAQ:IRMD) Logo

Sentiment for IRADIMED CORP (NASDAQ:IRMD)

IRADIMED CORP (NASDAQ:IRMD) institutional sentiment decreased to 1.16 in Q2 2019. Its down -0.41, from 1.57 in 2019Q1. The ratio is negative, as 29 active investment managers started new and increased stock positions, while 25 decreased and sold their stock positions in IRADIMED CORP. The active investment managers in our partner’s database now own: 3.39 million shares, up from 2.51 million shares in 2019Q1. Also, the number of active investment managers holding IRADIMED CORP in their top 10 stock positions increased from 0 to 1 for an increase of 1. Sold All: 9 Reduced: 16 Increased: 21 New Position: 8.

Iradimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging compatible products, and related accessories and services in the United States and internationally. The company has market cap of $246.49 million. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. It has a 32.95 P/E ratio. The firm also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories; iMagox MRI pulse oximeter; and iMagox MRI oximeter remote and display products.

The stock increased 1.31% or $0.28 during the last trading session, reaching $21.68. About 58,752 shares traded. IRadimed Corporation (NASDAQ:IRMD) has risen 4.28% since October 12, 2018 and is uptrending. It has outperformed by 4.28% the S&P500.

Analysts await IRadimed Corporation (NASDAQ:IRMD) to report earnings on October, 29. They expect $0.13 EPS, up 18.18 % or $0.02 from last year’s $0.11 per share. IRMD’s profit will be $1.48M for 41.69 P/E if the $0.13 EPS becomes a reality. After $0.17 actual EPS reported by IRadimed Corporation for the previous quarter, Wall Street now forecasts -23.53 % negative EPS growth.

Atria Investments Llc holds 2.38% of its portfolio in IRadimed Corporation for 771,677 shares. Rk Capital Management Llc owns 193,574 shares or 1.22% of their US portfolio. Moreover, Navellier & Associates Inc has 0.42% invested in the company for 131,727 shares. The Texas-based Ranger Investment Management L.P. has invested 0.38% in the stock. Cadence Capital Management Llc, a Massachusetts-based fund reported 125,751 shares.

More notable recent IRadimed Corporation (NASDAQ:IRMD) news were published by: Benzinga.com which released: “56 Biggest Movers From Friday – Benzinga” on September 16, 2019, also Benzinga.com with their article: “The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate – Benzinga” published on July 27, 2019, Seekingalpha.com published: “Stocks To Watch: Apple, IPOs And German Auto – Seeking Alpha” on September 07, 2019. More interesting news about IRadimed Corporation (NASDAQ:IRMD) were released by: Globenewswire.com and their article: “IRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System – GlobeNewswire” published on October 08, 2019 as well as Investorplace.com‘s news article titled: “10 High-Growth Stocks for the Return of the Bull – Investorplace.com” with publication date: January 18, 2019.

IRadimed Corporation (NASDAQ:IRMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.